USA - NASDAQ:ZYME - US98985Y1082 - Common Stock
ChartMill assigns a Buy % Consensus number of 84% to ZYME. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-21 | B. Riley Securities | Reiterate | Buy -> Buy |
| 2025-11-19 | Stifel | Maintains | Buy -> Buy |
| 2025-11-19 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-11-18 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-07 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-10-16 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-10-14 | HC Wainwright & Co. | Upgrade | Neutral -> Buy |
| 2025-10-10 | B. Riley Securities | Initiate | Buy |
| 2025-08-11 | Citigroup | Maintains | Buy -> Buy |
| 2025-07-03 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2025-05-20 | TD Securities | Initiate | Buy |
| 2025-03-11 | LifeSci Capital | Initiate | Outperform |
| 2025-03-10 | HC Wainwright & Co. | Maintains | Neutral -> Neutral |
| 2025-03-07 | Citigroup | Maintains | Buy -> Buy |
| 2024-12-19 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2024-12-16 | JP Morgan | Upgrade | Neutral -> Overweight |
| 2024-11-22 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-11-07 | Leerink Partners | Upgrade | Market Perform -> Outperform |
| 2024-11-04 | Citigroup | Maintains | Buy -> Buy |
| 2024-11-01 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2024-11-01 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-10-28 | Stifel | Maintains | Buy -> Buy |
| 2024-10-22 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-09-25 | HC Wainwright & Co. | Maintains | Neutral -> Neutral |
| 2024-09-18 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-08-02 | Stifel | Maintains | Buy -> Buy |
| 2024-06-06 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-05-07 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-05-03 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2024-05-03 | Citigroup | Maintains | Buy -> Buy |
18 analysts have analysed ZYME and the average price target is 25.25 USD. This implies a price increase of 5.1% is expected in the next year compared to the current price of 24.02.
The consensus rating for ZYMEWORKS INC (ZYME) is 84.4444 / 100 . This indicates that analysts generally have a positive outlook on the stock.
The number of analysts covering ZYMEWORKS INC (ZYME) is 18.